While the Overweight rating suggests Morgan Stanley's positive outlook on CNP's performance, the reduction in price target could imply a slightly moderated growth expectation or adjustment to market conditions. This news is likely to have a neutral to mildly negative short-term impact on CNP's stock price as the market digests the revised target.